Company Info






  Home > Archived Webinars >

French Transparency Regulations: An Overview for the Life Science Industry



 
Our Price: $395.00

Product Code: WB-7064
Qty:

Product Info
 
About the Product
Includes 1 Hour and 10 minute Windows Media Video File and PowerPoint presentations for immediate download.


After almost two years of drafts and debate, the so-called French Sunshine Act, was finally implemented by the French Ministry of Health by the Decree of May 21, 2013. Heavily motivated by both the US Sunshine Act, as well as local controversies such as the PIP breast implants and the case involving the drug Mediator, the French government has enacted the broad reporting requirements that entail disclosure from both pharmaceutical and medical device companies. However, the final Decree left many questions unanswered. Although interpretative guidelines have been published both by the health sector representative associations and French Ministry for Health and the process for disclosures on a single public website is taking form, compliance with the French Sunshine Act still remains a great challenge for many companies, since numerous issues remain to be clarified.
  • Detailed review of final Decree definitions and concepts
  • Pragmatic approach and a view to borderline cases and grey zones
  • Step by step guidance for disclosure process and obligations
  • Understanding the consequences for non-compliance
  • Methods for reporting system selection and implementation

Speakers:

Julie Yeni
Partner
Baker & McKenzie SCP

Sara Koski
Associate
Baker & McKenzie SCP


Participants that will find this webinar most beneficial will be those involved in pharmaceutical, medical device, biotechnology and diagnostic companies. Job titles of attendees that will be most applicable for this session will be:

  • Regulatory Affairs
  • Legal Affairs
  • General/Corporate Counsel
  • Compliance & Ethics

Share your knowledge of this product. Be the first to write a review »